Paying users zone. Data is covered by .

  • Get to Allergan PLC for $13.99, or

  • get to whole website for at least 3 months from $49.99.

 

$13.99


Free Cash Flow to Equity (FCFE)

Allergan PLC, FCFE calculation

USD $ in thousands

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income (loss) attributable to shareholders
(Income) loss attributable to noncontrolling interest
Net noncash charges
Changes in assets and liabilities, net of effects of acquisitions
Net cash provided by operating activities
Additions to property, plant and equipment
Additions to product rights and other intangibles
Proceeds from sales of property, plant and equipment
Proceeds from borrowings of long-term indebtedness, including credit facility
Debt issuance and other financing costs
Payments on debt, including capital lease obligations and credit facility
Free cash flow to equity (FCFE)
Item Description The company
FCFE Free cash flow to equity is the cash flow available to Allergan PLC's equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Allergan PLC's FCFE declined from 2015 to 2016 but then slightly increased from 2016 to 2017.

Top


Price to FCFE Ratio, Current

Allergan PLC, current P/FCFE calculation, comparison to benchmarks

 
No. shares of common stock outstanding
Selected Financial Data (USD $)
Free cash flow to equity (FCFE) (in thousands)
FCFE per share
Current share price (P)
Ratio
P/FCFE
Benchmarks
P/FCFE, Competitors
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/FCFE, Sector
Pharmaceuticals & Biotechnology
P/FCFE, Industry
Health Care

If company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.

Otherwise, if company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.

Top


Price to FCFE Ratio, Historical

Allergan PLC, historical P/FCFE calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1
Selected Financial Data (USD $)
Free cash flow to equity (FCFE) (in thousands)2
FCFE per share4
Share price1, 3
Ratio
P/FCFE5
Benchmarks
P/FCFE, Competitors
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/FCFE, Sector
Pharmaceuticals & Biotechnology
P/FCFE, Industry
Health Care

1 Data adjusted for splits and stock dividends.

2 See Details »

3 Close price on the filing date of Allergan PLC's Annual Report.

2017 Calculations

4 FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =

5 P/FCFE = Share price ÷ FCFE per share
= ÷ =

Ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders' equity. Allergan PLC's P/FCFE ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Top